BRCA1 interacts with FHL2 and enhances FHL2 transactivation function

FEBS Letters

Huang, Cuifen¹  Lu, Qiujun²  Ye, Qinong¹  Zhu, Jianhua¹  Zhong, Hongjun¹  Yan, Jinghua¹ 

[1] Beijing Institute of Biotechnology, 27 Tai-Ping Lu Rd, Beijing 100850, PR China;Beijing Institute of Radiation Medicine, Beijing 100850, PR China

关键词: BRCA1;    FHL2;    Protein–protein interaction;    Transactivation;   

DOI  :  10.1016/S0014-5793(03)00978-5

学科分类：生物化学/生物物理

来源: John Wiley & Sons Ltd.

【 摘 要 】

Germ-line mutations in BRCA1 are associated with an increased lifetime risk of developing breast and/or ovarian tumors. The BRCA1 gene product is a 220-kDa protein that contains a tandem of two BRCA1 C-terminal (BRCT) domains required for transcription. In an attempt to understand how BRCA1 exerts its function through BRCT domains, we search for partners of the BRCT domains of BRCA1. Using the yeast two-hybrid system, we identified the four and a half LIM-only protein 2 (FHL2) as a novel BRCA1 interacting protein. We demonstrate that BRCA1 and FHL2 can physically associate in vitro, in yeast, and in human cells. BRCA1 interacted with FHL2 through its second BRCT domain and the interaction of FHL2 with BRCA1 requires the last three LIM domains of FHL2. BRCA1 enhanced FHL2-mediated transcriptional activity in transient transfections. Tumor-derived transactivation-deficient BRCA1 mutants showed a reduced ability to enhance transactivation by FHL2. Lack of BRCA1 binding sites in the FHL2 completely abolished the FHL2 transactivation function. Reverse transcription polymerase chain reaction analysis showed that FHL2 mRNA levels may be downregulated in many breast cancer cell lines. These results suggest that the BRCA1–FHL2 interaction may be involved in transcriptional regulation and play a significant role in cancer cell growth.

【 授权许可】

Unknown